{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:04:45Z","timestamp":1790690685046,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012728","name":"National Cancer Institute Frederick Cancer Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bneo.2026.100221","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:27:00Z","timestamp":1773746820000},"page":"100221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD8+CD38+ T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlates"],"prefix":"10.1016","volume":"3","author":[{"given":"Nezar","family":"Mehanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-8493","authenticated-orcid":false,"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-8278","authenticated-orcid":false,"given":"Billel","family":"Gasmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2142-7356","authenticated-orcid":false,"given":"Theodora","family":"Anagnostou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3291-286X","authenticated-orcid":false,"given":"Oscar B.","family":"Lahoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Hassoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-4854","authenticated-orcid":false,"given":"Kylee","family":"Maclachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-6495","authenticated-orcid":false,"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-4318","authenticated-orcid":false,"given":"Neha","family":"Korde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-1091","authenticated-orcid":false,"given":"Urvi A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-2594","authenticated-orcid":false,"given":"Carlyn R.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-702X","authenticated-orcid":false,"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0469-839X","authenticated-orcid":false,"given":"David J.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.bneo.2026.100221_bib1","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.bneo.2026.100221_bib2","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1200\/JCO-24-01253","article-title":"Co-occurrence of cytogenetic abnormalities and high-risk disease in newly diagnosed and relapsed\/refractory multiple myeloma","volume":"43","author":"Kaiser","year":"2025","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.bneo.2026.100221_bib3","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bneo.2026.100221_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JOP.19.00335","article-title":"Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies","volume":"16","author":"Parrondo","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"12","key":"10.1016\/j.bneo.2026.100221_bib5","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100221_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","article-title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.bneo.2026.100221_bib7","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bneo.2026.100221_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bneo.2026.100221_bib9","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.3324\/haematol.2019.236588","article-title":"Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk","volume":"105","author":"Corre","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bneo.2026.100221_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00576-3","article-title":"Genomic characterization of functional high-risk multiple myeloma patients","volume":"12","author":"Soekojo","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.bneo.2026.100221_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54543-0","article-title":"Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy","volume":"15","author":"Lutz","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.bneo.2026.100221_bib12","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/bmt.2017.29","article-title":"Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication","volume":"52","author":"Arteche-L\u00f3pez","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bneo.2026.100221_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77941-y","article-title":"Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients","volume":"10","author":"Batorov","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.bneo.2026.100221_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41408-023-00920-9","article-title":"The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant","volume":"13","author":"Zanwar","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.bneo.2026.100221_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"10.1016\/j.bneo.2026.100221_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-021-00440-4","article-title":"Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"issue":"15","key":"10.1016\/j.bneo.2026.100221_bib17","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2017005447","article-title":"Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT","volume":"1","author":"Ho","year":"2017","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.bneo.2026.100221_bib18","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bneo.2026.100221_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s42003-019-0415-5","article-title":"diffcyt: Differential discovery in high-dimensional cytometry via high-resolution clustering","volume":"2","author":"Weber","year":"2019","journal-title":"Commun Biol"},{"issue":"11","key":"10.1016\/j.bneo.2026.100221_bib20","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ccell.2022.10.017","article-title":"Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma","volume":"40","author":"Sklavenitis-Pistofidis","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bneo.2026.100221_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cyto.a.22351","article-title":"From \u201ctruly na\u00efve\u201d to \u201cexhausted senescent\u201d T cells: when markers predict functionality","volume":"85","author":"Larbi","year":"2014","journal-title":"Cytometry A"},{"issue":"7","key":"10.1016\/j.bneo.2026.100221_bib22","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.4049\/jimmunol.1201556","article-title":"Differential localization of T-bet and Eomes in CD8 T cell memory populations","volume":"190","author":"McLane","year":"2013","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100221_bib23","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.4049\/jimmunol.0901533","article-title":"Human TCR-\u03b1\u03b2+ CD4\u2212 CD8\u2212 T cells can derive from CD8+ T cells and display an inflammatory effector phenotype","volume":"183","author":"Crisp\u00edn","year":"2009","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.bneo.2026.100221_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1105428","article-title":"C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer","volume":"5","author":"Rapp","year":"2016","journal-title":"Oncoimmunology"},{"issue":"1-2","key":"10.1016\/j.bneo.2026.100221_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/j.bneo.2026.100221_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"19","key":"10.1016\/j.bneo.2026.100221_bib27","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.bneo.2026.100221_bib28","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1182\/bloodadvances.2023011242","article-title":"Immune status and selection of patients for immunotherapy in myeloma: a proposal","volume":"8","author":"Dhodapkar","year":"2024","journal-title":"Blood Adv"},{"issue":"36","key":"10.1016\/j.bneo.2026.100221_bib29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/EDBK_159016","article-title":"Moving beyond autologous transplantation in multiple myeloma: consolidation, maintenance, allogeneic transplant, and immune therapy","volume":"35","author":"Krishnan","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"10.1016\/j.bneo.2026.100221_bib31","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1007\/s00277-022-04917-5","article-title":"Anti-CD38 antibody therapy for patients with relapsed\/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes","volume":"101","author":"Leleu","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bneo.2026.100221_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113395","article-title":"CD38: An important regulator of T cell function","volume":"153","author":"Li","year":"2022","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.bneo.2026.100221_bib33","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2026.100221_bib34","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/eji.201040726","article-title":"CD38 identifies a hypo-proliferative IL-13-secreting CD4+ T-cell subset that does not fit into existing naive and memory phenotype paradigms","volume":"41","author":"Scalzo-Inguanti","year":"2011","journal-title":"Eur J Immunol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100221_bib35","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100221_bib36","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:18:22Z","timestamp":1790687902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950328026000324"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100221","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD8+CD38+ T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlates","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100221"}}